Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;25(8):1019-1026.
doi: 10.1080/14656566.2024.2365329. Epub 2024 Jun 24.

Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance

Christian D Harding  1 , Ana Lucia Fuentes  1   2 , Atul Malhotra  1
Affiliations
Review

Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance

Christian D Harding et al. Expert Opin Pharmacother. 2024 Jun.

Abstract

Introduction: The efficacy of non-pharmacotherapeutic treatment of obstructive sleep apnea, a highly prevalent condition with serious cardiometabolic and neurocognitive health consequences, is well established. Supplementing traditional treatment strategies with medications can improve symptoms and reduce side effects. Efforts to identify medications that target the causes of sleep apnea have met with mixed success. However, this remains a worthwhile objective for researchers to pursue, given the potential benefit pharmacotherapy could bring to those patients who reject or struggle to adhere to existing treatments.

Areas covered: This article presents the case for obstructive sleep apnea pharmacotherapy including drugs that reduce the occurrence of apnea events, such as weight loss agents, ventilation activators and muscle and nervous system stimulants, drugs that alleviate symptoms, such as wake-promoting agents for excessive daytime sleepiness, and drugs that improve adherence to existing treatments, such as hypnotics. Literature was accessed from PubMed between 1 March 2024 and 18 April 2024.

Expert opinion: Exciting recent advances in both our understanding of obstructive sleep apnea pathology and in the techniques used to identify therapeutic agents and their targets combine to embolden a positive outlook for the expanded use of drugs in tackling this consequential disease.

Keywords: CPAP; pharmacotherapy; sleep apnea; treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

A Malhotra has relevant affiliations with the following organizations: Zoll, Livanova, Eli Lilly and Powell Mansfield.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Malhotra A, White DP. Obstructive sleep apnoea. Lancet. 2002. Jul 20;360(9328):237–245. doi: 10.1016/S0140-6736(02)09464-3 - DOI - PubMed
    1. Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019. Aug;7 (8):687–698. doi: 10.1016/S2213-2600(19)30198-5 - DOI - PMC - PubMed
    1. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004. Apr 28;291(16):2013–2016. doi: 10.1001/jama.291.16.2013 - DOI - PubMed
    1. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010. Jul 27;122(4):352–360. doi: 10.1161/CIRCULATIONAHA.109.901801 - DOI - PMC - PubMed
    1. Lal C, Strange C, Bachman D. Neurocognitive impairment in obstructive sleep apnea. Chest. 2012;141(6):1601–1610. doi: 10.1378/chest.11-2214 - DOI - PubMed

MeSH terms

Substances